RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: Implications for breast cancer development

Oncogene

Volumn 31, Issue 47, 2012, Pages 4912-4922

  Thaler, S ^a   Schmidt, M ^b   Schad, A ^b   Sleeman, J P ^a,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

breast cancer inhibition; estrogen receptor ; RASSF1A; senescence

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR ALPHA; INHIBITOR OF DIFFERENTIATION 1; PROTEIN BCL 2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CELL AGING; CELL CYCLE ARREST; CELL IMMORTALIZATION; CELL STRAIN MCF 7; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; EXPOSURE; FEMALE; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL AGING; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PROTEOLYSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84870066187     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.658     Document Type: Article

References (53)

1. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K et al. The tumor suppressor RASSF1A in human carcinogenesis: An update. Histol Histopathol 2005; 20: 645-663. (Pubitemid 40468282)
2. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE et al. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008; 10: R46.
3. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9: R57.
4. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R. Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 2005; 11: 2156-2162. (Pubitemid 40490172)
5. Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol 2005; 10: 3923-3933. (Pubitemid 40617644)
6. Mueller SO, Clark JA, Myers PH, Korach KS. Mammary gland development in adult mice requires epithelial and stromal estrogen receptor {alpha}. Endocrinology 2002; 143: 2357-2365. (Pubitemid 34521582)
7. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005; 19: 1951-1959. (Pubitemid 41124194)
8. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006; 58: 773-781. (Pubitemid 44833745)
9. Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-b-estradiol- induced Erk1/2 activation in breast cancer cells. J Biol Chem 2002; 277: 22558-22565.
10. Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996; 15: 1292-1300.
11. Razandi M, Pedram A, Park ST, Levin ER. Proximal events in signaling in plasma membrane estrogen receptors. J Biol Chem 2003; 278: 2701-2712. (Pubitemid 36801351)
12. Simoncini T, Hafezi-Moghadam A, Brizil DP, Ley K, Chin WW, Liao JK. Interaction of estrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407: 538-541.
13. Castoria G, Migliaccio A, Bilancio A, Di Domenico M, de Falco A, Lombardi M. PI3-kinase in concert with Src promotes the S-phase entry of estradiol-stimulated MCF-7 cells. EMBO J 2001; 20: 6050-6059. (Pubitemid 33049280)
14. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and precancerous breast. J Pathol 1999; 188: 237-244. (Pubitemid 29317764)
15. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998; 90: 37-42. (Pubitemid 28078079)
16. Lawson JS, Field AS, Champion S, Tran D, Ishikura H, Trichopoulos D. Low oestrogen receptor alpha expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet 1999; 354: 1787-1788.
17. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 1997; 57: 4987-4991. (Pubitemid 27498105)
18. Shaaban AM, Sloane JP, West CR, Foster CS. Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-a and Ki-67 expression. Am J Pathol 2002; 160: 597-604. (Pubitemid 34160337)
19. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davis MPA. Abnormal regulations of the oestrogen receptor in benign breast lesions. J Clin Pathol 2000; 53: 778-783.
20. Bartkova J, Rezaei N, Liontos M, Karakeidos P, Kletsas D, Issaeya N et al. Oncogeneinduced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637. (Pubitemid 44864442)
21. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444: 638-642. (Pubitemid 44864443)
22. Perillo B, Sasso A, Abbondanza C, Palumbo G. 17b-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol 2000; 20: 2890-2901. (Pubitemid 30183508)
23. Magro G, Bisceglia M, Michal M. Expression of steroid hormone receptors, their regulated proteins, and bcl-2 protein in myofibroblastoma of the breast. Histopathology 2000; 36: 515-521. (Pubitemid 30348776)
24. Yang Q, Sakurai T, Jing X, Utsunomiya H, Shan L, Nakamura Y et al. Expression of Bcl-2, but not Bax, correlates with estrogen receptor status and tumor proliferation in invasive breast carcinoma. Pathol Int 1999; 49: 775-780. (Pubitemid 29513291)
25. Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol 2007; 82: 85-90. (Pubitemid 46038271)
26. Reed JC, Haldar S, Croce CM, Cuddy MP. Complementation by BCL-2 and C-HA-RAS oncogenes in malignant transformation of rat embryo fibroblast. Mol Cell Biol 1990; 10: 4370-4374.
27. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumors induced in transgenic mice by co-operation between myc and bcl-2. Nature 1990; 348: 331-333. (Pubitemid 120029100)
28. Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992; 7: 1587-1594.
29. Gartel AL, Ye X, Goufman E, Shianova P, Hay N, Najmabandi F. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 2001; 98: 4510-4515. (Pubitemid 32295007)
30. Zhao JJ, Gjoerup OV, Subramanian RR, Cheng Y, Chen W, Roberts TM et al. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 2003; 3: 483-495. (Pubitemid 38340295)
31. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH et al. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 2000; 60: 1332-1340. (Pubitemid 30152003)
32. Peverali FA, Ramqvist T, Saffrich R, Barone MV, Philipson L. Regulation of G1 progression by E2A and Id helix-loop-helix proteins. EMBO J 1994; 13: 4291-4301.
33. Prabhu S, Ignatova A, Park ST, Sun XH. Regulation of the expression of cyclindependent kinase inhibitor p21 by E2A and Id. Mol Cell Biol 1997; 17: 5888-5896. (Pubitemid 27411095)
34. Ohtani N, Zebedee Z, Hout TJG, Stinson JA, Sugimoto M, Ohashi Y et al. Opposing effects of ETS and Id proteins on p16INK4a expression during cellular senescence. Nature 2001; 409: 1067-1070. (Pubitemid 32204062)
35. Swabrick A, Roy E, Allen T, Bishop JM. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA 2008; 105: 5402-5407. (Pubitemid 351753875)
36. Norton JD, Atherton GT. Coupling of cell growth control and apoptosis functions of Id proteins. Mol Cell Biol 1998; 18: 2371-2381. (Pubitemid 28152683)
37. Campell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. J Biol Chem 2001; 276: 9817-9824.
38. Faridi J, Wang L, Endemann G, Roth RA. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 2003; 9: 2933-2939. (Pubitemid 36993252)
39. Kasid A, Lippman ME, Papageorge AG, Lowy DR, Gelmann EP. Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science 1985; 228: 725-728. (Pubitemid 15063676)
40. Thaler S, Hähnel PS, Schad A, Dammann R, Schuler M. RASSF1A mediates p21Cip1/Waf1-dependent cell cycle arrest and senescence through modulation of the Raf-MEK-ERK pathway and inhibition of Akt. Cancer Res 2009; 69: 1748-1757.
41. Fowler AM, Solodin NM, Valley CC, Alarid ET. Altered target gene regulation controlled by estrogen receptor-a concentrations. Mol Endocrinol 2006; 20: 291-301. (Pubitemid 43153805)
42. Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M et al. Estrogen receptor alpha (ESR1) amplification is frequent in breast cancer. Nat Genet 2007; 39: 655-660. (Pubitemid 46676104)
43. Li T, Sotgia F, Vuolo MA, Li M, Yang WC, Pestell RG et al. Caveolin-1 mutations in human breast cancer: Functional association with estrogen-receptor alphapositive status. Am J Pathol 2006; 168: 1998-2013. (Pubitemid 43825319)
44. Kondo N, Toyama T, Sugiura H, Fujii Y, Yamashita H. miR-206 expression is downregulated in estrogen receptor alpha-positive human breast cancer. Cancer Res 2008; 68: 5004-5008.
45. Blanco-Aparicio C, Pérez-Gallego L, Pequeno B, Leal JF, Renner O, Carnero A. Mice expressing myrAKT in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 2007; 28: 584-594. (Pubitemid 46523354)
46. Chen L, Qui J, Yang C, Yang X, Chen X, Jiang J et al. Identification of a novel estrogen receptor beta1 binding partner, inhibitor of differentiation-1, and role of ERbeta1 in human breast cancer cells. Cancer Lett 2009; 278: 210-219.
47. Migliaccio A, Castoria G, Di Domenico M, De Falco A, Bilancio A, Auricchio F. Src is an initial target of sex steroid hormone action. Ann NY Acad Sci 2002; 963: 185-190. (Pubitemid 34721710)
48. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER. ERs associate with and recapitulate the production of caveolin: Implications for signalling and cellular actions. Mol Endocrinol 2002; 16: 100-115. (Pubitemid 34044501)
49. Moelling K, Schad K, Bosse M, Zimmermann S, Schwenker M. Regulation of Raf-Akt cross-talk. J Biol Chem 2002; 277: 31099-31106. (Pubitemid 34970815)
50. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007; 129: 1065-1079. (Pubitemid 46891036)
51. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705-711. (Pubitemid 32946946)
52. Boehm JS, Hession MT, Bulmer SE, Hahn WC. Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol 2005; 25: 6468-6474.
53. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97: 7963-7968. (Pubitemid 30460756)